Gaithersburg Lab to Expand Cancer Blood Test Access
The company plans to license its diagnostic technology to reach more clinical labs by 2027.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Should medical testing companies prioritize partnerships with local public programs over their own commercial licensing strategies?
Gaithersburg-based 20/20 BioLabs will host an investor webinar on November 4, 2026, to outline growth strategies. The discussion follows a September 2026 FDA meeting regarding multi-cancer early detection (MCED) testing.
Why it matters
The company aims to expand access to its OneTest diagnostic blood tests by licensing its tumor marker technology. This move aligns with broader regional initiatives, including over $520,000 in grants awarded to Maryland fire departments in March 2026 for cancer screening.
Official state grant data confirms $520,000 in funding distributed to 18 Maryland fire department groups in March 2026 for cancer screening programs. The regulatory framework for such blood-based testing, specifically for MCED, remains under investigation following the September 2026 FDA advisory meeting.
The players
20/20 BioLabs
A Gaithersburg-based laboratory company that develops and markets OneTest blood diagnostics for tumor marker detection.
Food and Drug Administration
The federal agency responsible for overseeing the safety and efficacy of medical devices and diagnostic tests in the United States.
The details
20/20 BioLabs utilizes a proprietary tumor marker approach for blood-based cancer detection. The company uses upper-arm capillary collection devices to streamline testing procedures and intends to offer these as a laboratory franchise. Management is currently pursuing a strategy to secure Medicare reimbursement for these diagnostics by the end of 2028.
Timeline
March 2026: Maryland fire departments were awarded over $520,000 for cancer screening.
September 23, 2026: The FDA held an advisory committee meeting on the Galleri MCED blood test.
November 4, 2026: 20/20 BioLabs will host an investor webinar.
2027: The company plans to begin licensing its tumor marker technology to clinical laboratories.
End of 2028: The company targets achieving Medicare reimbursement for MCED testing.
Health Landscape
The push for broader cancer screening adoption follows the FDA's regulatory trajectory for multi-cancer early detection (MCED) tests. This development sits within a growing market shift toward accessible blood-based tumor marker diagnostics for high-risk populations.
The integration of blood-based cancer screening into routine checkups is an evolving area of preventive care. Patients interested in how new screening technologies compare to traditional diagnostic tools should discuss the current availability and clinical evidence with their primary care physician.
The takeaway
Advancements in blood-based screening are changing the timeline for early cancer detection. Ask your doctor about which evidence-based screenings are appropriate for your specific age and medical history.
Further reading
For more on diagnostic developments, visit the Cancer section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical testing companies prioritize partnerships with local public programs over their own commercial licensing strategies?
